Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Multiple Cancer Types
A Three-Arm Study of ME-401 in Subjects with Relapsed / Refractory CLL / SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL
Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
This is the study of the PI3K? inhibitor ME-401 in subjects with relapsed / refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed / Refractory T-cell Lymphoma
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R / R T-cell lymphoma.